Navigation Links
free in Medical Technology

Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)

-Second Data Set Presented at MDS- PARIS, June 9 /PRNewswire/ -- Results from three placebo controlled studies conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set presented...

Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting

--First of 2 data sets to be released-- PARIS, June 8 /PRNewswire/ -- Results from two randomized, active-controlled clinical trials in patients with blepharospasm and cervical dystonia -- one placebo-controlled spasticity trial and one upper limb spasticity trial -- were presented at the ...

Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients

SEATTLE, April 28 /PRNewswire/ -- Results from two prospective, double-blind placebo controlled multi-center studies in patients with cervical dystonia and blepharospasm, and pooled European efficacy and safety data in patients with focal dystonia and upper limb spasticity will be presented at th...

New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer

BASEL, Switzerland, Dec. 10 /PRNewswire/ -- New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) continue to offer new and better treatment options for breast cancer patients al...

Leading Healthcare System Decreases MRSA Infection Rate by 53 Percent - Offers Protocol & Educational Materials Free of Charge to Other Organizations

Infant Deaths Spur Hard-Hitting, System-Wide Hand Washing Campaign That Drives Culture Change, Saves Lives CHARLOTTE, N.C., Sept. 16 /PRNewswire/ -- Novant Health, one of the top 10 integrated health systems in the country, dramatically increased hand-washing compliance from ...

Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials

- PFS data from Neuradiab(TM) compares favorably to data from other technologies - TSX: BMR TORONTO, July 17 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today release...

Family of Three Americans Become Pain Free and Improve Their Quality of Life With Stem Cell Treatment in Mexico

MONTERREY, Mexico, March 20 /PRNewswire/ -- Optimum Health Regeneration Center announced the successful treatment of an American family treated for pain management and impaired mobility. This New Mexico family, ranging in age from 52 to 78, all recorded significant improvements in reduced pain...

Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent

Phase II Investigational Trial Published in CANCER: the Journal of the American Cancer Society SEATTLE, Jan. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ; MTAX) announced today that results of a phase II clinical study, published in the jou...

Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology

MENLO PARK, Calif., Jan. 16 /PRNewswire/ -- Fundamental Applied Biology, Inc. (FAB) announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase IIB grant from the National Science Foundation. The $500,000 grant will be used to continue to develop FAB's cell-free ...

Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem

SWEDESBORO, N.J., Dec. 3 /PRNewswire/ -- Wedgewood Pharmacy has introduced the Refresh(TM) exchange-program, which lets veterinarians return expired custom-compounded medications for exchange, at no cost. The program is a compounding-pharmacy profession first. Through the program, the company ...

The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer

Presentation at ASCO Plenary Session Reports EORTC 40983 (EPOC) Intergroup Study Results CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Results of the randomized phase III EORTC 40983 Intergroup study, or EPOC study, demonstrate for the first time that peri-operative (pre and post surgery) FOLFO...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

...provide to patients who are affected by Type 1 Gaucher disease," said Dr. Atul Mehta, Clinical Director of the Lysosomal Storage Disorders Unit, Royal free Hospital, London. "Velaglucerase alfa appears to be an excellent choice for Type 1 Gaucher patients. The prospect of having another treatment option a...

OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer

...ne patients. Two patients remain without evidence of disease progression, and six patients were alive at time of data presentation. Median progression free survival was 3.3 months. This poster is available at www.celltherapeutics.com/investor_updates About (product) OPAXIO(TM) (paclitaxe...

John Legend and Gap Join (PRODUCT)RED(TM) to Help Eliminate AIDS in Africa with Exclusive (RED)ZONE Seating at Madison Square Garden

... section for John Legend's MSG show. Even better, with each (RED)ZONE ticket purchase, shoppers will automatically receive a second ticket to the show free of charge. Additionally, a select number of fans seated in the (RED)ZONE section will be randomly selected to go backstage to personally meet Legend a...

British Woman Celebrates a Year of Living Cancer-Free

...r (TaNK) cells as a treatment for leukemia. Her doctors at the Royal free Hospital in London recommended this experimental therapy after two years of...e key to a new type of advanced cancer therapy. Doctors at the Royal free injected Ms. Scott with natural killer (NK) cells taken from her daughter, ...

July 2009 Mayo Clinic Women's HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals

...practices in the United States. Energy therapies come from many cultures and are based on ideas about natural energy fields. They aim to create a free flow of energy by clearing, balancing and stimulating the human energy system. Though energy therapies are not well understood or always embraced by t...

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks

... of its product candidate Fluidosomes(TM)-tobramycin, whose unique microbiological profile sets it apart from other antibiotic formulations (including free tobramycin). Axentis Pharma (Switzerland) announced today that the Office of Orphan Products Development of the US Food and Drug Administration...

Dry Mouth Linked to Prescription and Over the Counter Drugs

...mpt to increase salivary production by drinking water; less than 58 percent say patients try taking over-the-counter saliva substitutes, chewing sugar free gum, or sucking on hard candy; and More than 60 percent of those surveyed consider diagnosing a patient with xerostomia after he or she exhibi...

Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease

... velaglucerase alfa ahead of commercial availability in the US. Under the conditions of the treatment protocol, Shire would provide velaglucerase alfa free of charge initially, in order to provide access to patients as quickly as possible. Velaglucerase alfa is made with Shire's proprietary technol...

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

...ment period with pixantrone compared to other agents. These additional late responders are likely to have a positive impact on analyses of progression free and overall survival and will be provided to the U.S. Food and Drug Administration during the 120-day update," stated James A. Bianco, M.D., Chief Exe...

School of Dentistry Studies Link Between Oral Health and Memory

...ions for health of our aging populations," Crout said. "With rates of Alzheimer's skyrocketing, imagine the benefits of knowing that keeping the mouth free of infection could cut down on cases of dementia." The research builds on an ongoing study of West Virginians aged 70 and older. Working with the...

CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer

... - 12 week progression free rate supports advancement into second stage of Simon 2-Stage designed trial - BRANFORD, Conn., June 17 /PRNewswire-FirstCall/ -- CuraGen Corpora...

New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring

...for the fiscal quarter year ended April 4, 2009, filed with the Securities and Exchange Commission (" SEC ") on May 6, 2009, which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do no...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

...inflammatory disease, ankylosing spondylitis," said Jurgen Braun, MD, lead physician at the Rheumazentrum Ruhrgebiet, Professor of Rheumatology at the free University of Berlin, lead study investigator. "As seen in this study, the possibilities of this new anti-TNF-alpha therapy are encouraging for both t...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

...ure through Day 50 (p-value 0.1177), orBec(R) did achieve statistical significance in other key secondary endpoints such as the proportion of patients free of GVHD at Day 50 (p-value 0.05) and Day 80 (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66%...

Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery

...for the fiscal quarter year ended April 4, 2009, filed with the Securities and Exchange Commission (" SEC ") on May 6, 2009, which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

... treatment cycle have responded according to standard Cheson criteria. Remissions appear to be durable without further treatment with a median relapse free interval of 13 months for the seven patients in the 0.06 mg/m(2) per day dose cohort reported at ASH in 2008(2). The most common adverse events (AEs) ...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

...9 months) and the median duration of response for the 48 responders was 6.8 months (95% CI; 5.4-11.0 months). Nineteen responders remained progression free at 6 months(1). "We continue to see the potential of Afinitor in multiple types of cancer," said Alessandro Riva, MD, Executive Vice President, ...

Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival

...or women who received chemotherapy alone. The hazard ratios for progression free survival and overall survival were 0.342 (p< 0.0001) and 0.348 (p=0.0005...h chemotherapy. "The improvement in overall survival and progression free survival together with the responses seen in this study are promising. We d...

Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

...nd the trial and compare very favorably with historical data with chemotherapy alone. Recent analysis also shows the median progression free survival of the patients enrolled in the first part of the study was 7.4 months, an additional promising early result. Patient dosing a...

IBM and EU Partners Create a Better Way to Fight AIDS Virus

...nificantly improves prediction of the right combination of drugs that works for the maximum amount of time." These innovations are being provided as a free tool that can help extend the lives of millions of people who are the victims of this disease. The system's predictions are near 76% accurate, ...

PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans

... proprietary liposomal technology we created an inhaled formulation that is free from irritating solvents and optimized for administration via an Investigat...L-CsA formulation is based on an artificial lung surfactant carrier. It is free of any irritating organic solvents and consists of unilamellar liposomes of...

Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment

...in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective (or increase remission rates or progress free survival) for treatment of relapsed or refractory aggressive NHL as determined by the FDA, the possibility that the NDA submission will not be complet...

Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative

...da, on 35 study patients over approximately 36 months, the survival rate for 97 percent of those patients was two years and the three-year progression free survival rate was 86 percent. Research was supervised by George Yoo, M.D., chief medical officer and member of the Head and Neck Cancer Multidisc...

GreenBytes Wards Off Germs and Costly Computer Repairs

...nce to function properly. GreenBytes provides this type of preventative service, and we specialize in Germ-Free cleaning, too." GreenBytes offers free service demonstrations to illustrate the condition of home and office equipment. Appointments are available through the company's Authorized Preventat...

Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults

...trials, 3.3% of patients randomized to 400 mg/day of Vimpat(R) were seizure free throughout the 12-week maintenance phase, vs. 0.9% of placebo patients. Seizure free days increased by 8% with 200 mg/day of Vimpat(R) and by 12% with 400 mg/da...

New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease

...for the fiscal quarter year ended April 4, 2009, filed with the Securities and Exchange Commission (" SEC ") on May 6, 2009, which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not...

BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting

...he long term loco-regional control rate of 100% combined with the very high percentage of patients in the mid and high dose groups that remain disease free at up to 36 months from treatment is very encouraging. As a result, OncoVEX GM-CSF clearly warrants further investigation in this setting. " ...

VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful

...ts included. These variations can mean the difference between being seizure free and suddenly having a seizure while driving on the freeway," said Dr. Brien...gistered journalists can access video, audio, text, graphics and photos for free and unrestricted use at http://www.mediaseed.tv . 05DC09-0022 ...

FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia

...Vanda files annual, quarterly and special reports, proxy and information statements, and other information with the SEC. These documents are available free of charge at the SEC's web site at www.sec.gov or from Vanda at www.vandapharma.com . STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT CAREFULLY ...
Other Tags
(Date:8/28/2014)... the most commonly diagnosed learning disability in the ... occurs when the regions of the brain that ... use of non-invasive functional neuroimaging tools has helped ... However, most prior work has focused on only ... gap in our understanding of how multiple brain ...
(Date:8/28/2014)... mould in homes could pose a significant health risk to ... the Journal of Allergy and Clinical Immunology . , ... different countries, the research has found that the presence of ... asthma sufferers, as well as increasing the likelihood of developing ... team at the University of Exeter Medical School and is ...
(Date:8/28/2014)... more action is needed to ensure safeguards are in ... in PLOS ONE , researchers from Monash University, ... - combining results from different studies - to look ... areas, to determine whether they actually protect biodiversity. ... protecting an area from human exploitation made common sense, ...
Breaking Biology News(10 mins):Dyslexic readers have disrupted network connections in the brain 2Indoor mold poses health risk to asthma sufferers 2Protected areas proven to protect biodiversity 2
(Date:8/30/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
(Date:8/30/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Lab ... The report then explores global and China’s top ... capacity, production value, and market share etc. , ...
(Date:8/30/2014)... 30, 2014 The federal judge ... ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific Corp. ... cases selected for one of the proceeding’s bellwether ... 18, 2014, U.S. District Judge Joseph R. Goodwin ... with Boston Scientific’s contention that a consolidated trial ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has ... and sleep apnea (a medical problem where the airway ... their bed partners of the rest they need to ... population snores and 20 million people in the United ... have been diagnosed and treated; and of those treated, ...
(Date:8/30/2014)... August 30, 2014 Removecomplaints.net, a well-known ... industry, has announced to offer guarantee of results with ... offer this guarantee because of its tremendous track record. ... clients from all over the world and received recommendation ... job. , On being asked about the announcement, ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Removecomplaints.net Announces Guaranteed Complaints Removal Services 2
Other Contents